New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:15 EDTAMPEAmpio's Ampion shows positive results in arthritis study extension
Ampio announced results of the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference in July. This 20-week extension of a multicenter study evaluated the safety and efficacy of a single intra-articular injection of Ampion treatment of inflammation-associated pain in symptomatic OA of the knee. At 20 weeks, the percentage of patients in the moderate-to-severe subgroup who reported a reduction in pain was significantly higher for patients who received Ampion - 50% - compared to those who received vehicle control - 25% -. Similar rates and severity of adverse events were observed in the Ampion and vehicle control groups. A single injection of Ampion was associated with sustained improvements in knee pain over 20 weeks.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
09:13 EDTAMPEAmpio to host conference call
Conference call to discuss Ampio's distribution to its existing stockholders of shares of common stock of Aytu BioScience, Inc, as well as Aytu's current business plans will be held on November 19 at 4:15 pm. Webcast Link
November 17, 2015
08:33 EDTAMPEAmpio to distribute shares of Aytu BioSciences to its stockholders
Ampio Pharmaceuticals announced it has established a record date of December 1 for its previously announced distribution to its stockholders of its shares of Common Stock of Aytu BioSciences. Ampio will distribute one share of Aytu common stock for every five shares of Ampio Common Stock owned as of the record date. This distribution will constitute over 70% of the Aytu shares outstanding at this time and approximately 90% of the Aytu shares owned by Ampio. The distribution date is expected to be January 4, 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use